CONTACT
+91 80 2808 2808
info@biocon.com

News - Posts

Biocon  /  News – Posts

Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance

  • Posted by: BIOCON

Biocon Limited enters into a settlement agreement with Celgene Corp.

  • Posted by: BIOCON

Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes

  • Posted by: BIOCON

Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention and Treatment of COVID-19

  • Posted by: BIOCON

Biocon Q1FY22 Revenue at Rs 1,808 Cr, Up 6%; EBITDA at Rs 437 Cr; Biosimilars Up 10 % at Rs 758 Cr; Research Services Up 41 % at Rs 595 Cr;

Biocon Q1FY22 Revenue at Rs 1,808 Cr, Up 6%; EBITDA at Rs 437 Cr; Biosimilars Up 10 % at Rs 758 Cr; Research Services Up 41 % at Rs 595 Cr;
  • Posted by: BIOCON

Biocon Q4FY21 Revenue at Rs 2,044 Cr, Up 26%; EBITDA at Rs 641 Cr; Up 68%

  • Posted by: BIOCON

Biocon Biologics’ New Monoclonal Antibodies Manufacturing Facility Wins ISPE’s 2021 Facility of the Year Honorable Mention Award

  • Posted by: BIOCON

Kiran Mazumdar-Shaw Joins Board of Trustees of Memorial Sloan Kettering Cancer Center, U.S.

  • Posted by: BIOCON

Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab

Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab
  • Posted by: BIOCON

Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, receives GMP compliance certificate from MHRA, UK

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>